Methods for detecting and treating hepatic cancers
AssigneeResearch Institute At Nationwide Children's Hospital
InventorsLi Chen, Yu Zhou, David Brigstock, Gail Besner
Life of this patent
Estimating the term…
Abstract
This disclosure provides methods for determining whether a subject is suffering from a liver cancer, such as hepatic carcinoma, comprising determining the expression level of miRNA-33b and/or miRNA46-a, in a sample of exosomes enriched from a body fluid of the subject, wherein low expression of the miRNA-33b and/or miRNA-46a as compared to a control is indicative of the subject suffering from a liver cancer, e.g., hepatic carcinoma. The subject may also be suffering from a fibrotic disease, liver fibrosis, and/or is or was infected with hepatitis B.
Claims23
A method for determining whether a subject is suffering from liver cancer, comprising determining the expression level of one or both of miRNA-33b and/or miRNA-46a in a sample of exosomes enriched from a body fluid of the subject.
A method for treating a subject suffering from liver cancer having low expression of comprising one or both of miRNA-33b and/or miRNA-46a in a sample of exosomes enriched from a body fluid of the subject, comprising administering an effective amount of a chemotherapy and/or an immunotherapy.
A method of treating a subject suffering from liver cancer comprising administering an effective amount of one or more of miRNA-33b, miRNA-33b equivalent, miRNA-33b enriched exosomes, miRNA-33b equivalent enriched exosome, miRNA-33b mimic, miRNA-33b mimic equivalent, miRNA-33b mimic enriched exosome, or miRNA-33b mimic equivalent enriched exosome, miRNA-46a, miRNA-46a equivalent, miRNA-46a enriched exosomes, miRNA-46a equivalent enriched exosome, miRNA-46a mimic, miRNA-46a mimic equivalent, miRNA-46a mimic enriched exosome, or miRNA-46a mimic equivalent enriched exosome to the subject.
A method of determining whether a subject suffering from liver cancer is more or less likely to be responsive to liver cancer therapy, comprising determining the expression level of expression of one or both of miRNA-33b and/or miRNA-46a in a sample enriched from the subject, wherein reduced expression of one or both of miRNA-33b and/or miRNA-46a as compared to a control indicates the subject is more likely to be responsive to therapy and/or wherein reduced increased expression of one or both of miRNA-33b and/or miRNA-46a as compared to a control indicates the subject is less likely to be responsive to the therapy.
-22. (canceled)
A kit for diagnosing liver cancer, comprising probes and/or primers for detecting miRNA-33b and/or miRNA-46a.
-27. (canceled)
A method of producing an miRNA-33b-enriched exosome comprising introducing one or more of miRNA-33b or miRNA-33b mimic or an equivalent of each thereof, or a polynucleotide encoding any one or more thereof into a cell, culturing the cell under conditions that favor cell proliferation, and isolating the miRNA-33b enriched exosome from the cell.
A method of producing an miRNA-46a-enriched exosome comprising introducing one or more of miRNA-46a or miRNA-46a mimic or an equivalent of each thereof, or a polynucleotide encoding any one or more thereof into a cell, culturing the cell under conditions that favor cell proliferation, and isolating the miRNA-46a enriched exosome from the cell.
A method of producing an miRNA-33b and miRNA-46a-enriched exosome comprising introducing one or more of miRNA-33b or miRNA-33b mimic, miRNA-46a or miRNA-46a mimic or an equivalent of each thereof, or a polynucleotide encoding any one or more thereof into a cell, culturing the cell under conditions that favor cell proliferation, and isolating the miRNA-33b and miRNA-46a enriched exosome from the cell.
The method of claim 20, wherein the miRNA or miRNA mimic or an equivalent of each thereof, or a polynucleotide encoding the same, is introduced into the cell by transfection or by electroporation.
(canceled)
Dependencies are inferred from the claim text.